We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).